Oct 29, 2021
GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Aug 10, 2021
RNS Number : 0791I MaxCyte, Inc. 10 August 2021       MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options                                                 Gaithersburg, Maryland - 10 August 2021 :   MaxCyte  (Nasdaq: MXCT) (LSE: MXCT, MXCN) , a leading provider of cell-engineering
Aug 09, 2021
RNS Number : 9261H MaxCyte, Inc. 09 August 2021         MaxCyte Signs Clinical and Commercial License with Sana Biotechnology   Agreement represents MaxCyte's 14 th strategic platform license (SPL)    Sana will use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform in conjunction
Jun 15, 2021
RNS Number : 8666B MaxCyte, Inc. 15 June 2021         MaxCyte Adds Two New Non-Executive Directors to Its Board   Gaithersburg, Maryland - 15 June 2021 :   MaxCyte (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, today announced the appointment of Rekha Hemrajani
May 25, 2021
RNS Number : 6449Z MaxCyte, Inc. 25 May 2021       FOR IMMEDIATE RELEASE   Celularity and MaxCyte Sign Strategic Platform Licence to Advance Celularity's Off-the-shelf Allogeneic Cellular Therapy Product Candidates   Celularity to utilize MaxCyte's Flow Electroporation ® technology and ExPERT ™
Feb 23, 2021
Released : February 23, 2021 07:00   RNS Number : 9618P MaxCyte, Inc. 22 February 2021                                   FOR IMMEDIATE RELEASE   MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences   GAITHERSBURG, MD , February 23, 2021 - MaxCyte, Inc., a global cell-based
Displaying 1 - 10 of 11